RetroNectin active Killer cells therapy (Chinese PLA General Hospital)

N/A

Report date: 2025/10/10 20:01:49

Base Information

Drug NameRetroNectin active Killer cells therapy (Chinese PLA General Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > RAK cells therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPla General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPla General Hospital
Inactive CompaniesN/A
Active IndicationsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A